Alvimedic心脏支架企业进军中国

2012-02-11 MedSci MedSci原创

1月11日,欧洲领先的心脏支架和导管品牌——土耳其Alvimedica在北京宣布,公司将携其最先进的技术和产品进入中国。 据了解,作为欧洲高科技领域的主要制造商,Alvimedica已经成为波士顿医疗、强生等支架领军企业的重要竞争对手。至去年11月底,Alvimedica已向40多个国家出口其产品,并正继续扩展其经销网络至其他国家。 据Alvimedica首席执行官澳博兹库尔特介绍:“公司

1月11日,欧洲领先的心脏支架和导管品牌——土耳其Alvimedica在北京宣布,公司将携其最先进的技术和产品进入中国。

据了解,作为欧洲高科技领域的主要制造商,Alvimedica已经成为波士顿医疗、强生等支架领军企业的重要竞争对手。至去年11月底,Alvimedica已向40多个国家出口其产品,并正继续扩展其经销网络至其他国家。

据Alvimedica首席执行官澳博兹库尔特介绍:“公司已经制定计划,经营目标是将产品推入全国各地介入性心脏特色医院及诊所。”他期望其在欧洲开发与投资得到认可的Alvimedica产品一样在中国能获得认可。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858553, encodeId=f75e1858553d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Apr 04 23:17:00 CST 2012, time=2012-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456004, encodeId=de7814560046d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457005, encodeId=ecfb145e005ee, content=<a href='/topic/show?id=26cd51530a7' target=_blank style='color:#2F92EE;'>#心脏支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51530, encryptionId=26cd51530a7, topicName=心脏支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea15828875, createdName=jiangfeng5069, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605654, encodeId=6a9c1605654a2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2012-04-04 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858553, encodeId=f75e1858553d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Apr 04 23:17:00 CST 2012, time=2012-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456004, encodeId=de7814560046d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457005, encodeId=ecfb145e005ee, content=<a href='/topic/show?id=26cd51530a7' target=_blank style='color:#2F92EE;'>#心脏支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51530, encryptionId=26cd51530a7, topicName=心脏支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea15828875, createdName=jiangfeng5069, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605654, encodeId=6a9c1605654a2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
    2012-02-13 hyf030
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858553, encodeId=f75e1858553d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Apr 04 23:17:00 CST 2012, time=2012-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456004, encodeId=de7814560046d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457005, encodeId=ecfb145e005ee, content=<a href='/topic/show?id=26cd51530a7' target=_blank style='color:#2F92EE;'>#心脏支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51530, encryptionId=26cd51530a7, topicName=心脏支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea15828875, createdName=jiangfeng5069, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605654, encodeId=6a9c1605654a2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858553, encodeId=f75e1858553d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Apr 04 23:17:00 CST 2012, time=2012-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456004, encodeId=de7814560046d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457005, encodeId=ecfb145e005ee, content=<a href='/topic/show?id=26cd51530a7' target=_blank style='color:#2F92EE;'>#心脏支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51530, encryptionId=26cd51530a7, topicName=心脏支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea15828875, createdName=jiangfeng5069, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605654, encodeId=6a9c1605654a2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 13 06:17:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]